Annual Financials for Deciphera Pharmaceuticals Inc.
Fiscal year is January-December. All values USD millions. |
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
Sales/Revenue
|
- | - | 25M | 42.09M | 96.15M | |
Sales Growth |
- | - | - | 68.35% | 128.45% | |
Cost of Goods Sold (COGS) incl. D&A |
150,000 | 317,000 | - | 5.36M | 9.39M | |
COGS excluding D&A |
- | - | - | 225,000 | 2.93M | |
Depreciation & Amortization Expense |
150,000 | 317,000 | 830,000 | 5.14M | 6.46M | |
Depreciation |
150,000 | 317,000 | 830,000 | 5.14M | 6.46M | |
Amortization of Intangibles |
- | - | - | - | - | |
COGS Growth |
- | 111.33% | - | - | 75.09% | |
Gross Income |
(150,000) | (317,000) | 24.17M | 36.72M | 86.76M | |
Gross Income Growth |
- | -111.33% | 7,724.61% | 51.94% | 136.24% | |
Gross Profit Margin |
- | - | - | - | 90.23% | NA |
|
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
SG&A Expense |
50.79M | 103.78M | 224.9M | 307.91M | 360.63M | |
Research & Development |
39.51M | 82.89M | 156.78M | 196.67M | 231.83M | |
Other SG&A |
11.27M | 20.9M | 68.12M | 111.25M | - | |
SGA Growth |
- | 104.36% | 116.70% | 36.91% | 17.12% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
- | - | - | - | 26.2M | |
EBIT after Unusual Expense |
- | - | - | - | (300.08M) | |
Non Operating Income/Expense |
746,000 | 4.33M | 8.54M | 4.7M | 113,000 | |
Non-Operating Interest Income |
- | - | - | - | - | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
95,000 | 84,000 | 67,000 | - | - | |
Interest Expense Growth |
- | -11.58% | -20.24% | - | - | |
Gross Interest Expense |
95,000 | 84,000 | 67,000 | - | - | |
Interest Capitalized |
- | - | - | - | - | |
Pretax Income |
(50.28M) | (99.85M) | (192.26M) | (266.49M) | (299.96M) | |
Pretax Income Growth |
- | -98.58% | -92.54% | -38.61% | -12.56% | |
Pretax Margin |
- | - | - | - | -311.98% | NA |
Income Tax |
- | - | - | - | - | |
Income Tax - Current Domestic |
- | - | - | - | - | |
Income Tax - Current Foreign |
- | - | - | - | - | |
Income Tax - Deferred Domestic |
- | - | - | - | - | |
Income Tax - Deferred Foreign |
- | - | - | - | - | |
Income Tax Credits |
- | - | - | - | - | |
Equity in Affiliates |
- | - | - | - | - | |
Other After Tax Income (Expense) |
- | - | - | - | - | |
Consolidated Net Income |
(50.28M) | (99.85M) | (192.26M) | (266.49M) | (299.96M) | |
Minority Interest Expense |
- | - | - | - | - | |
Net Income |
(50.28M) | (99.85M) | (192.26M) | (266.49M) | (299.96M) | |
Net Income Growth |
- | -98.58% | -92.54% | -38.61% | -12.56% | |
Net Margin Growth |
- | - | - | - | -311.98% | NA |
Extraordinaries & Discontinued Operations |
- | - | - | - | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
(50.28M) | (99.85M) | (192.26M) | (266.49M) | (299.96M) | |
Preferred Dividends |
- | - | - | - | - | |
Net Income Available to Common |
(50.28M) | (99.85M) | (192.26M) | (266.49M) | (299.96M) | |
EPS (Basic) |
(2.99) | (2.82) | (4.48) | (4.78) | (5.16) | |
EPS (Basic) Growth |
- | 5.64% | -58.95% | -6.53% | -8.10% | |
Basic Shares Outstanding |
16.79M | 35.39M | 42.87M | 55.78M | 58.08M | |
EPS (Diluted) |
(2.99) | (2.82) | (4.48) | (4.78) | (5.16) | |
EPS (Diluted) Growth |
- | 5.64% | -58.95% | -6.53% | -8.10% | |
Diluted Shares Outstanding |
16.79M | 35.39M | 42.87M | 55.78M | 58.08M | |
EBITDA |
(50.79M) | (103.78M) | (199.9M) | (266.05M) | (267.42M) | |
EBITDA Growth |
- | -104.36% | -92.61% | -33.09% | -0.51% | |
EBITDA Margin |
- | - | - | - | -278.13% | NA |